Radioimmunoscintigraphy of prostate cancer

R. Joseph Babaian, Lamk M. Lamki

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The development of hybridoma technology has increased research efforts and clinical applications in the area of radioimmunodetection. Despite the many investigative antibodies directed against prostatic tissue or prostate cancer cell lines, only two have been tested in clinical trials. A 111In-labeled antibody directed against prostate-specific antigen, the best available serum tumor marker for prostate cancer, has shown poor sensitivity in limited clinical radioimmunoimaging trials. Monoclonal antibodies against prostatic acid phosphatase have shown better imaging results, particularly at higher antibody doses (≥40mg). The limitations of this antibody include the poor results in detecting soft tissue lesions, including the primary lesion; the development of human antimouse antibodies in 50% of the patients at doses >-40 mg; the expense of the antibody; and the fact that better results are currently attainable by other less expensive imaging modalities. If and when a more suitable antibody or fragment is developed, the prospect of improved staging and new treatments using immunologic conjugates carrying therapeutic agents may become realities. Until such time, prostatic cancer will be staged with other currently available imaging modalities and conventional therapies with their limitations will remain state of the art.

Original languageEnglish
Pages (from-to)309-321
Number of pages13
JournalSeminars in Nuclear Medicine
Volume19
Issue number4
DOIs
Publication statusPublished - 1989

Fingerprint

Radioimmunodetection
Prostatic Neoplasms
Antibodies
Clinical Trials
Immunoglobulin Fragments
Hybridomas
Human Development
Prostate-Specific Antigen
Tumor Biomarkers
Therapeutics
Biomarkers
Monoclonal Antibodies
Technology
Cell Line
Research

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Radioimmunoscintigraphy of prostate cancer. / Babaian, R. Joseph; Lamki, Lamk M.

In: Seminars in Nuclear Medicine, Vol. 19, No. 4, 1989, p. 309-321.

Research output: Contribution to journalArticle

Babaian, R. Joseph ; Lamki, Lamk M. / Radioimmunoscintigraphy of prostate cancer. In: Seminars in Nuclear Medicine. 1989 ; Vol. 19, No. 4. pp. 309-321.
@article{6b88cb980a5e493898651fa19b43c761,
title = "Radioimmunoscintigraphy of prostate cancer",
abstract = "The development of hybridoma technology has increased research efforts and clinical applications in the area of radioimmunodetection. Despite the many investigative antibodies directed against prostatic tissue or prostate cancer cell lines, only two have been tested in clinical trials. A 111In-labeled antibody directed against prostate-specific antigen, the best available serum tumor marker for prostate cancer, has shown poor sensitivity in limited clinical radioimmunoimaging trials. Monoclonal antibodies against prostatic acid phosphatase have shown better imaging results, particularly at higher antibody doses (≥40mg). The limitations of this antibody include the poor results in detecting soft tissue lesions, including the primary lesion; the development of human antimouse antibodies in 50{\%} of the patients at doses >-40 mg; the expense of the antibody; and the fact that better results are currently attainable by other less expensive imaging modalities. If and when a more suitable antibody or fragment is developed, the prospect of improved staging and new treatments using immunologic conjugates carrying therapeutic agents may become realities. Until such time, prostatic cancer will be staged with other currently available imaging modalities and conventional therapies with their limitations will remain state of the art.",
author = "Babaian, {R. Joseph} and Lamki, {Lamk M.}",
year = "1989",
doi = "10.1016/S0001-2998(89)80023-6",
language = "English",
volume = "19",
pages = "309--321",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Radioimmunoscintigraphy of prostate cancer

AU - Babaian, R. Joseph

AU - Lamki, Lamk M.

PY - 1989

Y1 - 1989

N2 - The development of hybridoma technology has increased research efforts and clinical applications in the area of radioimmunodetection. Despite the many investigative antibodies directed against prostatic tissue or prostate cancer cell lines, only two have been tested in clinical trials. A 111In-labeled antibody directed against prostate-specific antigen, the best available serum tumor marker for prostate cancer, has shown poor sensitivity in limited clinical radioimmunoimaging trials. Monoclonal antibodies against prostatic acid phosphatase have shown better imaging results, particularly at higher antibody doses (≥40mg). The limitations of this antibody include the poor results in detecting soft tissue lesions, including the primary lesion; the development of human antimouse antibodies in 50% of the patients at doses >-40 mg; the expense of the antibody; and the fact that better results are currently attainable by other less expensive imaging modalities. If and when a more suitable antibody or fragment is developed, the prospect of improved staging and new treatments using immunologic conjugates carrying therapeutic agents may become realities. Until such time, prostatic cancer will be staged with other currently available imaging modalities and conventional therapies with their limitations will remain state of the art.

AB - The development of hybridoma technology has increased research efforts and clinical applications in the area of radioimmunodetection. Despite the many investigative antibodies directed against prostatic tissue or prostate cancer cell lines, only two have been tested in clinical trials. A 111In-labeled antibody directed against prostate-specific antigen, the best available serum tumor marker for prostate cancer, has shown poor sensitivity in limited clinical radioimmunoimaging trials. Monoclonal antibodies against prostatic acid phosphatase have shown better imaging results, particularly at higher antibody doses (≥40mg). The limitations of this antibody include the poor results in detecting soft tissue lesions, including the primary lesion; the development of human antimouse antibodies in 50% of the patients at doses >-40 mg; the expense of the antibody; and the fact that better results are currently attainable by other less expensive imaging modalities. If and when a more suitable antibody or fragment is developed, the prospect of improved staging and new treatments using immunologic conjugates carrying therapeutic agents may become realities. Until such time, prostatic cancer will be staged with other currently available imaging modalities and conventional therapies with their limitations will remain state of the art.

UR - http://www.scopus.com/inward/record.url?scp=0024746088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024746088&partnerID=8YFLogxK

U2 - 10.1016/S0001-2998(89)80023-6

DO - 10.1016/S0001-2998(89)80023-6

M3 - Article

C2 - 2678482

AN - SCOPUS:0024746088

VL - 19

SP - 309

EP - 321

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 4

ER -